Study S000668

Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide - a Randomized Controlled Trial.

ClinicalTrials.gov record

Registration

Registration: NCT07391267
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: DOUBLE
Status: NOT_YET_RECRUITING
Enrollment: 90
Start: 2026-02-01
Primary completion: 2028-12-31
Lead sponsor: Institute of Liver and Biliary Sciences, India
Conditions: Chronic Kidney Diseases; MAFLD
Interventions: DRUG:Semaglutide Oral Tablet; OTHER:Placebo; OTHER:Standard medical treatment
Results posted: FALSE

Registered primary outcomes

Time to first occurrence of a composite primary outcome event defined as persistent eGFR decline of greater than or equal to 50 percentage from trial start, reaching ESRD, death from kidney disease or death from cardiovascular disease. [3 months, 6 months, 12 months,18 months and 24 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.